8 Most Promising Biotech Stocks to Buy Now

7. BridgeBio Pharma, Inc. (NASDAQ:BBIO)

On May 8, Evercore ISI raised its price target on BridgeBio Pharma, Inc. (NASDAQ:BBIO) to $130 from $125. It maintained an “Outperform” rating on the stock.

On May 7, BridgeBio Pharma, Inc. (NASDAQ:BBIO) posted first-quarter 2026 results, showing $194.5 million in total revenue. The revenue comprised of $180.6 million from U.S. Attruby net product sales, fueled by prescribing growth and patient persistence.

The company said demand grew across patient types, pointing out strong uptake among treatment-naive patients. It noted global traction following a Brazil approval.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) said real-world evidence showed Attruby reduced diuretic intensification by 43% versus tafamidis, citing an analysis released on medRxiv and an independent study presented at SCAI.

Pipeline activity continued, with the company stating it submitted an NDA for BBP-418 and plans filings for encaler​​et and infigratinib in 2026.

The firm reported $940.2 million in cash as of March 31 and authorized a $500 million share repurchase program.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) identifies and promotes novel medications to treat Mendelian diseases. Its development pipeline contains product candidates at various stages of development, from early discovery to late-stage development.